CD274 and triple-negative breast carcinoma: On the other hand, immunotherapy studies in breast cancer like the one conducted by Schmid et al. [144] for triple-negative breast cancer (TNBC) showed that the combination of PD-L1 inhibitor Atezolizumab with nab-paclitaxel resulted in improvement in overall survival with a median of 9.5-month (HR 0.62, 95% CI 0.45–0.86) in patients with PD-L1 positive immune infiltration [144].